Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Tax Provisions: 2019-2024

Historic Tax Provisions for Catalyst Pharmaceuticals (CPRX) over the last 6 years, with Dec 2024 value amounting to $52.9 million.

  • Catalyst Pharmaceuticals' Tax Provisions rose 37.02% to $18.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.7 million, marking a year-over-year increase of 18.78%. This contributed to the annual value of $52.9 million for FY2024, which is 51.18% up from last year.
  • As of FY2024, Catalyst Pharmaceuticals' Tax Provisions stood at $52.9 million, which was up 51.18% from $35.0 million recorded in FY2023.
  • In the past 5 years, Catalyst Pharmaceuticals' Tax Provisions ranged from a high of $52.9 million in FY2024 and a low of -$33.1 million during FY2020.
  • Its 3-year average for Tax Provisions is $36.5 million, with a median of $35.0 million in 2023.
  • In the last 5 years, Catalyst Pharmaceuticals' Tax Provisions plummeted by 2,257.30% in 2020 and then skyrocketed by 139.84% in 2021.
  • Catalyst Pharmaceuticals' Tax Provisions (Yearly) stood at -$33.1 million in 2020, then spiked by 139.84% to $13.2 million in 2021, then surged by 64.13% to $21.6 million in 2022, then spiked by 61.62% to $35.0 million in 2023, then skyrocketed by 51.18% to $52.9 million in 2024.